Remoxy: Phase I data

Top-line data from a double-blind, placebo- and active-controlled, triple-dummy, 6-way crossover, U.S. Phase I trial in 32 evaluable healthy volunteers with a history of non-dependent recreational opioid use showed that both whole and chewed 40 mg Remoxy met the primary endpoint of significantly lower drug liking vs. whole/crushed 40 mg oxycodone ER or crushed 40 mg oxycodone IR (p<0.05 for both). Chewed Remoxy also significantly delayed the time to peak drug liking vs. crushed oxycodone ER or crushed oxycodone IR (p<0.05). Furthermore, no subject was able to chew Remoxy for >1.5 minutes despite an allotted time of 10 minutes due to the unpleasant taste/texture of the product. Data were published in Pain Medicine and will be presented at the American Pain Society Meeting in Austin in May. ...